oritavancin
TAR-ORI-SD001
Phase 2 small_molecule completed
Quick answer
oritavancin for Staphylococcal Skin Infections is a Phase 2 program (small_molecule) at Targanta Netherlands B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Targanta Netherlands B.V.
- Indication
- Staphylococcal Skin Infections
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed